Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
暂无分享,去创建一个
R. Rudick | E. Fisher | J. Simon | L. Jacobs | J-C Lee | R.A. Rudick | E. Fisher | J.-C. Lee | J. Simon | L. Jacobs | Jar‐chi Lee | Jack H. Simon | Elizabeth Fisher | Lawrence Jacobs
[1] Gianpaolo Donzelli,et al. Catch-Up Growth in Short-at-Birth NICU Graduates , 2000, Hormone Research in Paediatrics.
[2] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[3] W. I. McDonald,et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.
[4] R. Rudick,et al. Neurodegeneration in Multiple Sclerosis: Relationship to Neurological Disability , 1999 .
[5] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[6] J. Simon. Contrast‐enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis , 1997, Journal of magnetic resonance imaging : JMRI.
[7] P. Matthews,et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.
[8] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[9] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[10] H. Wiśniewski,et al. The role of oligodendroglia and astroglia in Wallerian degeneration of the optic nerve. , 1973, Brain research.
[11] M. Rovaris,et al. A Longitudinal Magnetic Resonance Imaging Study of the Cervical Cord in Multiple Sclerosis , 1997, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[12] J A Frank,et al. MRI studies of multiple sclerosis: Implications for the natural history of the disease and for monitoring effectiveness of experimental therapies , 1996, Multiple sclerosis.
[13] B. Weinstock-Guttman,et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients , 1995 .
[14] A J Thompson,et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.
[15] R. Herndon,et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis , 1999, Neurology.
[16] Jeanelle Sheeder,et al. Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .
[17] J H Simon,et al. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. , 1987, AJNR. American journal of neuroradiology.
[18] D. Li,et al. Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis. , 1999, Neurology.
[19] J H Simon,et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. , 1998, Annals of neurology.
[20] A. Thompson,et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.
[21] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[22] Roland Martin,et al. Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.
[23] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.